Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
Large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year.
Among the 17 largest pharma companies analyzed in a Fierce Pharma review of annual reports, only five logged a head count increase in 2025*. In contrast, the immediate impact of job reductions on efficiency was evident: All but one company recorded growth in revenue per employee.
Pharma giants are apparently entering a correction phase in terms of size. Back in 2022, only three of the 17 firms we tracked recorded a workforce cutback.
This head count contraction comes as the biopharma industry braces for a massive $300 billion patent cliff in prescription drug revenues between 2025 and 2030. To maintain profits, many companies have resorted to cost cuts and layoffs. The trend wi